Today: 20 July 2026
Browse Category

NYSE:BSX 22 October 2025 - 16 January 2026

Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra, Inc. shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced plans to acquire the clot-removal device maker in a roughly $14.5 billion deal. The stock reached an after-hours high of $369.84 but remained about $23 short of the $374 offer price, reflecting lingering merger risk and time before closing.
15 January 2026
Boston Scientific (BSX) Stock After Hours on Dec. 24, 2025: Key Moves, Today’s Fresh Analysis, and What to Watch Before Markets Reopen

Boston Scientific (BSX) Stock After Hours on Dec. 24, 2025: Key Moves, Today’s Fresh Analysis, and What to Watch Before Markets Reopen

Boston Scientific Corporation wrapped up a holiday-shortened Christmas Eve session with a modest move in regular trading — and a small uptick in after-hours. With U.S. markets closed on Christmas Day and set to reopen Friday, investors now have a narrow window to digest today’s commentary and position for the next full session. AP News+2Barron's+2
25 December 2025
Boston Scientific (BSX) Stock News Today: UBS Reiterates $140 Target, RBC Raises to $130 as 2026 Catalysts Come Into Focus

Boston Scientific (BSX) Stock News Today: UBS Reiterates $140 Target, RBC Raises to $130 as 2026 Catalysts Come Into Focus

Boston Scientific Corporation is back in the spotlight on Wednesday, December 17, 2025, as fresh Wall Street commentary and a new round of target-price updates reframe the conversation around the medtech leader’s 2026 setup—especially in fast-growing cardiac categories like electrophysiology and left atrial appendage closure. Investing.com+1
17 December 2025
Boston Scientific (BSX) Stock on December 10, 2025: Why Shares Are Sliding While the Growth Story Stays Intact

Boston Scientific (BSX) Stock on December 10, 2025: Why Shares Are Sliding While the Growth Story Stays Intact

As of December 10, 2025, Boston Scientific stock is trading around $92.5 per share, roughly 15–16% below its 52‑week high of $109.50 set on September 9. The stock has logged seven straight down days, including a 1.4% drop to $92.53 on December 9, on unusually heavy volume of 12.7 million shares versus a 50‑day average of about 9.1 million. MarketWatch
10 December 2025
Boston Scientific (BSX) Extends Losing Streak: What Tuesday’s Close Means Before the Bell on December 10, 2025

Boston Scientific (BSX) Extends Losing Streak: What Tuesday’s Close Means Before the Bell on December 10, 2025

On Tuesday, December 9, 2025, Boston Scientific stock slipped about 1.4% to roughly $92.5 per share, on heavier‑than‑usual volume of around 12.7 million shares, versus an average near 8.9 million. MarketBeat+1 That marked another down day in an early‑December pullback that has left BSX trading at the bottom of its 50‑day range and about 15% below its 52‑week high of $109.50, set in September. MarketBeat+1
10 December 2025
Boston Scientific Stock (BSX) on December 3, 2025: Insider Sales, EU Device Win and Strong 2026 Price Targets

Boston Scientific Stock (BSX) on December 3, 2025: Insider Sales, EU Device Win and Strong 2026 Price Targets

Boston Scientific Corporation stock remains a closely watched name in large‑cap medical technology as 2025 winds down. On December 3, 2025, the BSX share price is hovering just below the psychological $100 mark, while new headlines about insider selling, fresh European device approvals and updated analyst targets shape the near‑term story for the stock. Yahoo Finance
4 December 2025
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific’s Q3 report blew past expectations. Marlborough, MA-based Boston Scientific posted reported net income of $755 M and adjusted EPS of $0.75 timesunion.com chartmill.com, topping the $0.71–$0.72 analysts’ forecast. CEO Mike Mahoney called it “another exceptional quarter of strong performance” prnewswire.com, fueled by robust growth across all businesses. Total sales were $5.065 B, up 20.3% from a year ago prnewswire.com. Importantly, organic revenue grew 15.3%, well above the 12–14% guidance range. U.S. revenues surged ~27% in Q3 investing.com, reflecting strong demand for its interventional cardiology and MedSurg devices.
22 October 2025
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks are starting today on cautiously optimistic footing. Futures were little changed this morning after a batch of earnings delivered both relief and warnings. Netflix shocked investors with a rare earnings miss, sending its stock down ~6–7% in pre-market tradingreuters.com. And chipmaker Texas Instruments sank nearly 9% after issuing a bleak sales forecast, which in turn dragged down other semiconductor namesreuters.com. Those disappointments put a slight chill on Nasdaq futures. “We’re at a bit of a point of indecision, where nobody feels particularly strongly about anything,” noted Michael Green of Simplify Asset Management, observing that even earnings surprises aren’t moving markets much in this wait-and-see environmentreuters.com.
Go toTop